Distribution of the “composite” colposcopic histopathological diagnoses by the confirmatory diagnostic procedure (colposcopy or histopathology) among HIV-infected women in Pune, India.

<p>Distribution of the “composite” colposcopic histopathological diagnoses by the confirmatory diagnostic procedure (colposcopy or histopathology) among HIV-infected women in Pune, India.</p

Unadjusted (bivariate) and multivariable ordinal logistic regression analysis of predictors of disease prevalence for ordinal outcome in three categories of increasing disease severity (No CIN, CIN1, CIN2, ≥CIN3) confirmed by composite colposcopic-histopathological diagnosis among HIV-infected women in Pune, India.

<p>Abbreviations: OR: Odds ratio; CI: Confidence intervals; INR: Indian Rupees; BMI: Body Mass Index; ART: Antiretroviral therapy; STI: Sexually transmitted infection; WHO: World Health Organization.</p>*<p>The number of covariates that could be included in the multivariable regression model was dependent on the number of event outcomes for that analysis to avoid over-fitting of the models. Hence only 10 covariates were included in the multivariable model. Covariates were deemed scientifically important and selected <i>a priori</i> along with covariates that were significant in unadjusted (bivariate) analysis.</p>∧<p>The exchange rate at the time of the study was approximately 45 INR (Indian Rupees) per US$such that Indian Rupees 1,000 are the equivalent of US$ 22.</p

Distribution of sociodemographic variables as per final disease outcomes (confirmed by colposcopic histopathological diagnoses) among HIV-infected women in Pune, India.

<p>Abbreviations: IQR: interquartile ratio (25th percentile and 75th percentile), INR: Indian Rupees; BMI: Body Mass Index; ART: Antiretroviral therapy; STI: Sexually transmitted infection; WHO: World Health Organization.</p>∧<p>The exchange rate at the time of the study was approximately 45 INR (Indian Rupees) per US$such that Indian Rupees 1,000 are the equivalent of US$ 22.</p

Study enrollment, procedures, and main outcomes.

<p>The flow diagram shows the number of HIV-infected women who were offered participation, those enrolled in the study, list of study procedures, and final diagnosis through the composite colposcopic-histopathological assessment.</p

Hazard ratios for second line failure or third line regimen start.

<p>Hazard ratios for second line failure or third line regimen start.</p

Cumulative incidence after HAART initiation of starting a third line regimen or failing a second line regimen.

<p>Cumulative incidence after HAART initiation of starting a third line regimen or failing a second line regimen.</p

Cohort description.

<p>Categorical variables are reported as percentages (count).</p><p>Continuous variables are reported as medians (interquartile range).</p><p>Cohort description.</p

Second line virologic failure. Patient descriptive statistics.

<p>Categorical variables are reported as percentages (count).</p><p>Continuous variables are reported as medians (interquartile range).</p><p>Second line virologic failure. Patient descriptive statistics.</p

Characteristics of the Study Population.

<p>HIV-infected persons who initiated antiretroviral therapy (ART), received rifamycin-based anti-tuberculosis therapy while on ART, and did not have tuberculosis at a site of disease that required extended therapy (e g, central nervous system, bone/joint, or pericardium).</p><p>Parentheses include percentages unless otherwise noted.</p><p>TB: tuberculosis</p><p>Baseline CD4+ lymphocyte and HIV-1 RNA measurements were at the time of ART initiation.</p><p>* The proportions of all persons at each study site with TB (the row percentages)—were as follows:</p><p>Argentina: 3%; Brazil: 7%; Chile: 4%; Honduras: 9%; Mexico: 4%; Peru: 16%</p><p>^ Median (IQR) values before tuberculosis diagnosis: 74 (34-191)</p><p># Median (IQR values before tuberculosis diagnosis: 4.4 log₁₀ (2.6-5.2)</p

Baseline and Treatment Characteristics of the 253 Tuberculosis Patients Included in the Study, According to Length of Follow-up/Survival and Duration of Anti-tuberculosis Therapy.

<p>Data are presented as number (%) except as shown.</p><p>P-values are for the comparison of all 4 groups, using the chi-squared test.</p><p>* the comparison limited to persons with > 6 months of follow-up and known TB treatment duration (the two inner columns) was not statistically significant. If not noted by * the statistical significance of the comparison between these two groups was similar to that of all 4 groups.</p><p>=Data available for 222 patients.</p><p>^ Data available for 222 patients.</p><p># Data available for 171 patients.</p><p>+ Data available for 228 patients.</p><p>a median time between TB diagnosis and ART start: 95 days (IQR: 53, 142)</p><p>b median time between ART start and TB diagnosis: 142 days (IQR: 30, 568)</p